JoinClinicalTrials.com

• Confocal Microscopy Evaluation of Margin Clearance in Basal Cell Carcinomas in Mohs Surgery

  NCT03610620

  Condition:   Basal Cell Carcinoma
  Intervention:   Procedure: Vivascope 2500 ex-vivo fluorescent confocal microscope
  Sponsors:   Emily Woodhouse;   Mavig GmbH
  Recruiting
• RCM to Diagnose BCC - Reflectance Confocal Microscopy to Diagnose Basal Cell Carcinoma

  NCT03331874

  Condition:   Basal Cell Carcinoma
  Intervention:   Diagnostic Test: Reflectance Confocal Microscopy
  Sponsor:   Julie Dawson
  Recruiting
• A Study of IO103 in Montanide Adjuvant for Basal Cell Carcinoma

  NCT03714529

  Condition:   Basal Cell Carcinoma
  Intervention:   Biological: PD-L1
  Sponsors:   Herlev and Gentofte Hospital;   University of Copenhagen
  Recruiting
• Nivolumab Alone or Plus Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma

  NCT03521830

  Condition:   Basal Cell Carcinoma
  Interventions:   Drug: Nivolumab;   Drug: Ipilimumab
  Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   Bristol-Myers Squibb
  Recruiting
• Neoadjuvant Vismodegib in Patients With Large and/or Recurrent Resectable Basal Cell Carcinoma

  NCT03035188

  Condition:   Basal Cell Carcinoma
  Intervention:   Drug: Vismodegib
  Sponsor:   SRH Wald-Klinikum Gera GmbH
  Recruiting
• Open-Label Dose Escalation Trial to Evaluate Dose Limiting Toxicity and Maximum Tolerated Dose of Microneedle Arrays Containing Doxorubicin (D-MNA) in Basal Cell Carcinoma

  NCT03646188

  Condition:   Basal Cell Carcinoma
  Interventions:   Drug: Placebo-containing MNA;   Drug: 25 µg doxorubicin-containing MNA;   Drug: 50 µg doxorubicin-containing MNA;   Drug: 100 µg doxorubicin-containing MNA;   Drug: 200 µg doxorubicin-containing MNA
  Sponsors:   SkinJect, Inc.;   University of Colorado, Denver
  Not yet recruiting
• Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer

  NCT03180528

  Condition:   Skin Basal Cell Carcinoma
  Intervention:   Drug: Remetinostat
  Sponsors:   Kavita Sarin;   Medivir
  Recruiting
• Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).

  NCT03573401

  Condition:   Superficial Basal Cell Carcinoma
  Interventions:   Combination Product: Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT);   Combination Product: Placebo Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)
  Sponsor:   Biofrontera Bioscience GmbH
  Recruiting
• Arsenic Trioxide and Itraconazole in Treating Patients With Advanced Basal Cell Cancer

  NCT02699723

  Condition:   Skin Basal Cell Carcinoma
  Interventions:   Drug: Arsenic Trioxide;   Drug: Itraconazole;   Other: Laboratory Biomarker Analysis
  Sponsors:   Jean Yuh Tang;   National Cancer Institute (NCI)
  Not yet recruiting
• (Cost)-Effectiveness of Optical Coherence Tomography (OCT) in Basal Cell Carcinoma (BCC)

  NCT03848078

  Conditions:   Basal Cell Carcinoma;   Optical Coherence Tomography
  Intervention:   Device: Optical Coherence Tomography
  Sponsors:   Maastricht University Medical Center;   ZonMw: The Netherlands Organisation for Health Research and Development
  Recruiting
• Vitamin D as a Nutritional Neoadjuvant During Photodynamic Therapy of Basal Cell Carcinoma

  NCT03467789

  Conditions:   Basal Cell Carcinoma;   Basal Cell Nevus Syndrome
  Interventions:   Dietary Supplement: Vitamin D3 prior to first visit;   Dietary Supplement: Vitamin D3 prior to second visit;   Radiation: Photodynamic therapy;   Dietary Supplement: Maintenance Vitamin D3
  Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
  Recruiting
• Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma

  NCT01835626

  Conditions:   Locally Advanced Basal Cell Carcinoma;   Skin Cancer;   Cutaneous Malignancy
  Interventions:   Drug: Vismodegib;   Radiation: Radiation therapy
  Sponsors:   Sue Yom;   Genentech, Inc.
  Recruiting
• A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinoma

  NCT03534947

  Conditions:   Basal Cell Carcinoma;   Basal Cell Carcinoma of Skin, Site Unspecified;   Skin Cancer;   Invasive Carcinoma
  Interventions:   Drug: Sonidegib;   Drug: Imiquimod;   Procedure: Surgery;   Other: Best supportive care
  Sponsor:   Melanoma Institute Australia
  Recruiting
• Relationship Between Pharmacokinetics and Safety of Vismodegib - OPTIVISMO-1

  NCT03610022

  Conditions:   Metastatic Basal Cell Carcinoma;   Locally Advanced Basal Cell Carcinoma
  Intervention:   Drug: Treatment with vismodegib
  Sponsor:   University Hospital, Bordeaux
  Recruiting
• Study Evaluating the Efficacy and Safety of 0.05% Ingenol Mebutate (Picato® 500) in the Treatment of Basal Cell Carcinoma

  NCT03546166

  Condition:   Carcinoma
  Intervention:   Drug: Picato 0.05% Topical Gel
  Sponsor:   Centre Hospitalier Universitaire de Nice
  Not yet recruiting
• Vitamin D and Photodynamic Therapy for Treatment of BCC in BCNS

  NCT03483441

  Conditions:   Basal Cell Nevus Syndrome;   Basal Cell Carcinoma
  Interventions:   Other: Placebo pill;   Dietary Supplement: Vitamin D;   Drug: PDT
  Sponsors:   The Cleveland Clinic;   University of Arizona;   Harvard Medical School
  Recruiting
• Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)

  NCT03897036

  Condition:   Carcinoma, Basal Cell
  Intervention:   Drug: CX-4945
  Sponsor:   Senhwa Biosciences, Inc.
  Recruiting
• Efficiency of Presurgical Basal Cell Carcinoma Margin Mapping

  NCT03420846

  Condition:   Carcinoma, Basal Cell
  Intervention:   Other: OCT Mapped
  Sponsors:   Michelson Diagnostics Ltd.;   Skin Care Network Ltd.
  Recruiting
• VISmodegib for ORbital and Periocular Basal Cell Carcinoma

  NCT02436408

  Condition:   Carcinoma, Basal Cell
  Intervention:   Drug: Vismodegib
  Sponsor:   University of Michigan Rogel Cancer Center
  Recruiting
• French National Database of Rare Dermatological Cancers

  NCT03210935

  Conditions:   Adnexal Tumor of Skin;   Merkel Cell Carcinoma;   Advanced Basal Cell Carcinoma Requiring Systemic Treatment
  Intervention:  
  Sponsor:   University Hospital, Lille
  Recruiting
• To Assess The Efficacy And Safety Of Vismodegib And Radiotherapy In Advanced Basal Cell Carcinoma

  NCT02956889

  Condition:   Carcinoma, Basal Cell
  Interventions:   Drug: Vismodegib;   Radiation: Radiotherapy
  Sponsor:   Istituto Clinico Humanitas
  Recruiting
• Topical Laser-assisted Combination Chemotherapy for Basal Cell Carcinoma― a Clinical Study

  NCT03541252

  Condition:   Carcinoma, Basal Cell
  Intervention:   Drug: AFL-assisted cisplatin+5-FU
  Sponsor:   Merete Haedersdal
  Recruiting
• Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome

  NCT03703310

  Condition:   Basal Cell Nevus Syndrome
  Interventions:   Drug: Patidegib Topical Gel, 2%;   Drug: Patidegib Topical Gel, Vehicle
  Sponsor:   PellePharm, Inc.
  Recruiting
• PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy

  NCT03132636

  Condition:   Carcinoma, Basal Cell
  Intervention:   Drug: REGN2810
  Sponsors:   Regeneron Pharmaceuticals;   Sanofi
  Recruiting
• Diagnosing Melanoma, Squamous Cell Carcinoma and Basal Cell Carcinoma Using the Spectra-Scope

  NCT03069846

  Condition:   Skin Cancer
  Intervention:   Device: Spectra-Scope
  Sponsor:   Sung Hyun Pyun
  Recruiting
• Use Of Oral Itraconazole In Patients With Locally Limited Basocellular Carcinoma Of Skin.

  NCT03972748

  Conditions:   Basal Cell Carcinoma;   Hedgehog Pathway
  Intervention:   Drug: Itraconazole 200 mg
  Sponsor:   Hospital de Clinicas de Porto Alegre
  Recruiting
• Study Assessing the Safety and Performance of Smart Matrix®

  NCT03742726

  Conditions:   Basal Cell Carcinoma;   Squamous Cell Carcinoma
  Intervention:   Device: Smart Matrix scaffold
  Sponsor:   Smart Matrix Limited
  Recruiting
• Molecular Characterization of Cutaneous Tumors

  NCT03092830

  Conditions:   Squamous Cell Carcinoma;   Basal Cell Carcinoma
  Intervention:   Genetic: Molecular testing of DNA/RNA from skin tumors, SCC/BCC
  Sponsor:   Rabin Medical Center
  Recruiting
• Reflectance Confocal Microscopy in Basal Cell Carcinoma

  NCT02623101

  Condition:   Carcinoma, Basal Cell
  Interventions:   Device: Reflectance confocal microscopy;   Procedure: Punch biopsy;   Procedure: Surgical excision
  Sponsors:   Radboud University;   ZonMw: The Netherlands Organisation for Health Research and Development;   Mavig GmbH
  Recruiting
• Harmonics-based in Vivo Optical Virtual Biopsy

  NCT01980264

  Conditions:   Melanoma (Skin);   Basal Cell Carcinoma;   Squamous Cell Carcinoma
  Intervention:   Device: Harmonic Generation Microscopy
  Sponsors:   National Taiwan University Hospital;   National Health Research Institutes, Taiwan
  Recruiting
• A Window of Opportunity Trial of Intratumoral Injection of Copaxone® in Patients With Percutaneously Accessible Tumors

  NCT03982212

  Conditions:   Cutaneous Squamous Cell Carcinoma;   Squamous Cell Carcinoma;   Basal Cell Carcinoma
  Intervention:   Drug: Copaxone
  Sponsor:   University of Kansas Medical Center
  Recruiting
• Intraoperative Detection of Residual BCC by Fast Raman

  NCT03482622

  Conditions:   Carcinoma, Basal Cell;   Intraoperative BCC Detection by Fast Raman Device
  Intervention:   Diagnostic Test: Fast Raman
  Sponsors:   University of Nottingham;   Nottingham University Hospitals NHS Trust;   Circle Nottingham NHS Treatment Centre
  Not yet recruiting
• Elucid Labs AIDA™ - Labelled Image Acquisition Protocol

  NCT03621462

  Conditions:   Melanoma (Skin);   Basal Cell Carcinoma of the Skin;   Squamous Cell Carcinoma of the Skin
  Intervention:   Device: Artificial Intelligence Dermatology Assistant (AIDA™)
  Sponsor:   Elucid Labs Inc.
  Not yet recruiting
• T-VEC in Non-melanoma Skin Cancer

  NCT03458117

  Conditions:   Non-melanoma Skin Cancer;   Basal Cell Carcinoma;   Squamous Cell Carcinoma;   Cutaneous Lymphoma;   Merkel Cell Carcinoma
  Intervention:   Genetic: Talimogene Laherparepvec (T-VEC)
  Sponsor:   University of Zurich
  Recruiting
• Cancer Risk in Carriers of the Gene for Xeroderma Pigmentosum

  NCT00046189

  Conditions:   Xeroderma Pigmentosum;   Basal Cell Carcinoma;   Squamous Cell Carcinoma;   Melanoma;   Skin Cancer
  Intervention:  
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors

  NCT03734913

  Conditions:   Basal Cell Carcinoma;   Medulloblastoma;   Adenocarcinoma of Esophagogastric Junction;   Small Cell Lung Cancer;   Neuroendocrine Neoplasm;   Glioblastoma
  Intervention:   Drug: ZSP1602
  Sponsor:   Guangdong Zhongsheng Pharmaceutical Co., Ltd.
  Recruiting
• How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes

  NCT03370861

  Conditions:   Autoimmunity;   Melanoma;   Merkel Cell Carcinoma;   Squamous Cell Carcinoma of the Skin;   Basal Cell Carcinoma;   Skin Cancer
  Intervention:   Biological: Immunotherapy
  Sponsor:   Washington University School of Medicine
  Recruiting
• Electronic Skin Surface Brachytherapy for Cutaneous Basal Cell and Squamous Cell Carcinoma

  NCT02131805

  Conditions:   Cutaneous Basal Cell;   Squamous Cell Carcinoma
  Interventions:   Radiation: Electronic Skin Surface Brachytherapy;   Behavioral: Quality of life assessment
  Sponsors:   Memorial Sloan Kettering Cancer Center;   Lynn Cancer Institute
  Recruiting
• Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or Lymphoma

  NCT03775525

  Conditions:   Advanced Cancer;   Gastric Cancer;   Breast Cancer;   Pancreatic Cancer;   Prostate Cancer Metastatic;   Colo-rectal Cancer;   Solid Tumor;   Solid Carcinoma;   Solid Carcinoma of Stomach;   Cancer of Stomach;   Lymphoma;   Sarcoma;   Cutaneous T Cell Lymphoma;   Head and Neck Squamous Cell Carcinoma;   Basal Cell Carcinoma;   Cutaneous T-cell Lymphoma;   Cutaneous Squamous Cell Carcinoma
  Intervention:   Drug: GZ17-6.02
  Sponsors:   Genzada Pharmaceuticals USA, Inc.;   Translational Drug Development
  Recruiting
• ACCEPTABILITY AND WRITING FREQUENCY OF ADVANCED DIRECTIVES IN ONCO-DERMATOLOGY PATIENTS

  NCT03822988

  Conditions:   Advance Directives;   Oncology;   Skin Cancer;   Melanoma;   Skin Lymphoma;   Skin Squamous Cell Carcinoma;   Metastatic Basal Cell Carcinoma
  Intervention:   Other: no intervention, only complete a survey
  Sponsor:   Central Hospital, Nancy, France
  Recruiting
• Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

  NCT02834013

  Conditions:   Acinar Cell Carcinoma;   Adenoid Cystic Carcinoma;   Adrenal Cortex Carcinoma;   Adrenal Gland Pheochromocytoma;   Anal Canal Neuroendocrine Carcinoma;   Anal Canal Undifferentiated Carcinoma;   Angiosarcoma;   Apocrine Neoplasm;   Appendix Mucinous Adenocarcinoma;   Bartholin Gland Transitional Cell Carcinoma;   Basal Cell Carcinoma;   Bladder Adenocarcinoma;   Cervical Adenocarcinoma;   Cervical Clear Cell Adenocarcinoma;   Cholangiocarcinoma;   Chordoma;   Colorectal Squamous Cell Carcinoma;   Desmoid-Type Fibromatosis;   Endometrial Transitional Cell Carcinoma;   Endometrioid Adenocarcinoma;   Esophageal Neuroendocrine Carcinoma;   Esophageal Undifferentiated Carcinoma;   Extrahepatic Bile Duct Carcinoma;   Extramammary Paget Disease;   Fallopian Tube Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fibromyxoid Tumor;   Gallbladder Carcinoma;   Gastric Neuroendocrine Carcinoma;   Gastric Squamous Cell Carcinoma;   Gastric Undifferentiated Carcinoma;   Gastrointestinal Stromal Tumor;   Gestational Trophoblastic Tumor;   Giant Cell Carcinoma;   Intestinal Neuroendocrine Carcinoma;   Intrahepatic Cholangiocarcinoma;   Lung Carcinoid Tumor;   Lung Sarcomatoid Carcinoma;   Major Salivary Gland Carcinoma;   Malignant Odontogenic Neoplasm;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Testicular Sex Cord-Stromal Tumor;   Metaplastic Breast Carcinoma;   Metastatic Malignant Neoplasm of Unknown Primary;   Minimally Invasive Lung Adenocarcinoma;   Mixed Mesodermal (Mullerian) Tumor;   Mucinous Adenocarcinoma;   Mucinous Cystadenocarcinoma;   Nasal Cavity Adenocarcinoma;   Nasal Cavity Carcinoma;   Nasopharyngeal Carcinoma;   Nasopharyngeal Papillary Adenocarcinoma;   Nasopharyngeal Undifferentiated Carcinoma;   Oral Cavity Carcinoma;   Oropharyngeal Undifferentiated Carcinoma;   Ovarian Adenocarcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Germ Cell Tumor;   Ovarian Mucinous Adenocarcinoma;   Ovarian Squamous Cell Carcinoma;   Ovarian Transitional Cell Carcinoma;   Pancreatic Acinar Cell Carcinoma;   Pancreatic Neuroendocrine Carcinoma;   Paraganglioma;   Paranasal Sinus Adenocarcinoma;   Paranasal Sinus Carcinoma;   Parathyroid Gland Carcinoma;   PEComa;   Peritoneal Mesothelioma;   Pituitary Gland Carcinoma;   Placental Choriocarcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Pseudomyxoma Peritonei;   Rare Disorder;   Scrotal Squamous Cell Carcinoma;   Seminal Vesicle Adenocarcinoma;   Seminoma;   Serous Cystadenocarcinoma;   Small Intestinal Adenocarcinoma;   Small Intestinal Squamous Cell Carcinoma;   Solid Neoplasm;   Spindle Cell Neoplasm;   Squamous Cell Carcinoma of the Penis;   Teratoma With Somatic-Type Malignancy;   Testicular Non-Seminomatous Germ Cell Tumor;   Thyroid Gland Carcinoma;   Tracheal Carcinoma;   Transitional Cell Carcinoma;   Ureter Adenocarcinoma;   Ureter Squamous Cell Carcinoma;   Urethral Adenocarcinoma;   Urethral Squamous Cell Carcinoma;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified;   Vulvar Carcinoma
  Interventions:   Procedure: Biospecimen Collection;   Biological: Ipilimumab;   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers

  NCT03816332

  Conditions:   Clinical Stage III Cutaneous Melanoma AJCC v8;   Clinical Stage III Merkel Cell Carcinoma AJCC v8;   Clinical Stage IV Cutaneous Melanoma AJCC v8;   Clinical Stage IV Merkel Cell Carcinoma AJCC v8;   High-Frequency Microsatellite Instability;   Kidney Transplant Recipient;   Metastatic Basal Cell Carcinoma;   Metastatic Melanoma;   Metastatic Skin Squamous Cell Carcinoma;   Pathologic Stage III Cutaneous Melanoma AJCC v8;   Pathologic Stage III Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIIA Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIIB Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIIC Cutaneous Melanoma AJCC v8;   Pathologic Stage IIID Cutaneous Melanoma AJCC v8;   Pathologic Stage IV Cutaneous Melanoma AJCC v8;   Pathologic Stage IV Merkel Cell Carcinoma AJCC v8;   Unresectable Melanoma
  Interventions:   Biological: Ipilimumab;   Biological: Nivolumab;   Drug: Prednisone;   Drug: Tacrolimus
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Familial Investigations of Childhood Cancer Predisposition

  NCT03050268

  Conditions:   Acute Leukemia;   Adenomatous Polyposis;   Adrenocortical Carcinoma;   AML;   BAP1 Tumor Predisposition Syndrome;   Carney Complex;   Choroid Plexus Carcinoma;   Constitutional Mismatch Repair Deficiency Syndrome;   Diamond-Blackfan Anemia;   DICER1 Syndrome;   Dyskeratosis Congenita;   Emberger Syndrome;   Familial Acute Myeloid Leukemia;   Familial Adenomatous Polyposis;   Fanconi Anemia;   Familial Cancer;   Familial Wilms Tumor;   Familial Neuroblastoma;   GIST;   Hereditary Breast and Ovarian Cancer;   Hereditary Paraganglioma-Pheochromocytoma Syndrome;   Hodgkin Lymphoma;   Juvenile Polyposis;   Li-Fraumeni Syndrome;   Lynch Syndrome;   MDS;   Melanoma Syndrome;   Multiple Endocrine Neoplasia Type 1;   Multiple Endocrine Neoplasia Type 2;   Neuroblastoma;   Neurofibromatosis Type 1;   Neurofibromatosis Type II;   Nevoid Basal Cell Carcinoma Syndrome;   Non Hodgkin Lymphoma;   Noonan Syndrome and Other Rasopathy;   Overgrowth Syndromes;   Pancreatic Cancer;   Peutz-Jeghers Syndrome;   Pheochromocytoma/Paraganglioma;   PTEN Hamartoma Tumor Syndrome;   Retinoblastoma;   Rhabdoid Tumor Predisposition Syndrome;   Rhabdomyosarcoma;   Rothmund-Thomson Syndrome;   Tuberous Sclerosis;   Von Hippel-Lindau Disease
  Intervention:  
  Sponsor:   St. Jude Children's Research Hospital
  Recruiting
• Skin Cancer Prevention With Nicotinamide in Transplant Recipients - Pilot Trial

  NCT03769285

  Conditions:   Non-melanoma Skin Cancer;   Carcinoma, Squamous Cell;   Carcinoma, Basal Cell
  Interventions:   Drug: Nicotinamide;   Drug: Placebo oral capsule
  Sponsors:   Women's College Hospital;   Canadian Institutes of Health Research (CIHR);   The Kidney Foundation of Canada;   NOW Foods;   Natural Life Nutrition
  Recruiting
• Tissue Sample Collection From Patients With Head and Neck Cancer and From Healthy Participants

  NCT00898638

  Condition:   Head and Neck Cancer
  Interventions:   Other: biologic sample preservation procedure;   Other: medical chart review
  Sponsors:   Vanderbilt University Medical Center;   National Cancer Institute (NCI)
  Recruiting
• Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia.

  NCT03889899

  Conditions:   Skin Cancer;   Mucosal Neoplasm of Oral Cavity;   Soft Tissue Neoplasm
  Intervention:   Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
  Sponsor:   Alpha Tau Medical LTD.
  Not yet recruiting
• Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal and Superficial Soft Tissue Neoplasia (DaRT)

  NCT03886181

  Conditions:   Skin Cancer;   Mucosal Neoplasm of Oral Cavity;   Soft Tissue Neoplasm
  Intervention:   Device: Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
  Sponsor:   Alpha Tau Medical LTD.
  Not yet recruiting
• Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia (DaRT)

  NCT03737734

  Conditions:   Skin Cancer;   Mucosal Neoplasm of Oral Cavity;   Soft Tissue Neoplasm
  Intervention:   Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
  Sponsor:   Alpha Tau Medical LTD.
  Recruiting